RESEARCH PAPER
Experiences of COPD patients with existing smoking cessation programs and their preferences for improvement - a qualitative analysis
I. Aumann 1, 2  
,  
L. Tedja 1,  
 
 
More details
Hide details
1
Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Hannover, Germany
2
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany
Publish date: 2016-08-24
 
Tobacco Induced Diseases 2016;14(August):31
KEYWORDS:
ABSTRACT:
Background:
Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD). For current smokers who are diagnosed with COPD, their first treatment option is to stop smoking. Motivation is necessary for long-term smoking cessation; therefore, when designing smoking cessation programs, the patients’ needs and preferences should be considered. We focused on COPD patients’ experiences with existing smoking cessation programs and evaluated their preferences for the improvement of these programs.

Methods:
We conducted 18 guideline-based interviews with COPD patients between April and June 2014 in Germany. Each patient with COPD, who was a current or past smoker and had made at least one attempt to quit smoking in the past 5 years, was included in the study. We audiotaped, verbatim transcribed, and evaluated the interviews, using content analysis.

Results:
The patients had broad and different experiences with pharmaceutical, behavioral, and alternative approaches that supported or negatively influenced the smoking cessation process. Pharmaceuticals were viewed as an expensive alternative with many side effects although they helped to stop cravings for a few moments. Furthermore, the bad structure and impersonal content of the seminars for smoking cessation negatively influenced group cohesion, and therefore degrading the patients’ motivation to stop smoking. Alternative methods, such as acupuncture and hypnosis were mostly ineffective in smoking cessation, but in some cases, served as motivational strategies.

Conclusions:
Negative experiences with smoking cessation were explained by the patients’ lack of motivation or resolution. Other negative experiences, such as the structure of seminars for smoking cessation and the high price of pharmaceuticals should be addressed through policy changes to increase the patients’ motivation to quit smoking.

CORRESPONDING AUTHOR:
I. Aumann   
Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str. 1, 30159 Hannover, Germany
 
REFERENCES (29):
1. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PloS Med. 2006;3:e442.
2. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the diagnosis, management and prevention of COPD Updated 2014. URL: http://www.goldcopd.it/materia.... Accessed 17 Apr 2015.
3. Lopez AD. Global burden of disease and risk factors. New York: Oxford University Press; World Bank; 2006.
4. Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013;42:559–63.
5. Centers for Disease Control and Prevention: Smoking & Tobacco Use: Quitting Smoking http://www.cdc.gov/tobacco/dat.... Accessed 17 Apr 2015.
6. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.
7. Wilson JS, Elborn JS, Fitzsimons D. ‘It’s not worth stopping now’: why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. J Clin Nurs. 2011;20:819–27.
8. Van Eerd EAM, Risør MB, van Rossem CR, van Schayck OCP, Kotz D. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease-a qualitative analysis. BMC Fam Pract. 2015;16:164.
9. Eklund B, Nilsson S, Hedman L, Lindberg I. Why do smokers diagnosed with COPD not quit smoking? - a qualitative study. Tob Induc Dis. 2012;10:17.
10. van Eerd EAM, van Rossem C, Spigt MG, Wesseling G, van Schayck OCP, Kotz D. Do We Need Tailored Smoking Cessation Interventions for Smokers with COPD? A Comparative Study of Smokers with and without COPD Regarding Factors Associated with Tobacco. Respiration. 2015;90:211.
11. Flick U. An introduction to qualitative research. 4th ed. Los Angeles: Sage Publications; 2009.
12. Mayring P: Qualitative Content Analysis. Forum: Qualitative Social Research, [S.l.], v. 1, n. 2, june 2000. ISSN 1438-5627. http://www.qualitativeresearch.... Accessed 22 Aug 2016.
13. Das Fünfte Buch Sozialgesetzbuch – Gesetzliche Krankenversicherung – (Artikel 1 des Gesetzes vom 20. Dezember 1988, BGBl. I S. 2477, 2482), das durch Artikel 1a des Gesetzes vom 31. Juli 2016 (BGBl. I S. 1937) geändert worden ist.
14. West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14:166–71.
15. World Health Organization. WHO report on the global tobacco epidemic, 2013: Enforcing bans on tobacco advertising, promotion and sponsorship. Geneva: World Health Organization; 2013. p. 2013.
16. Eriksen MP, Mackay J, Schluger NW, Islami F, Drope J: The Tobacco Atlas, Fourth Edition. Atlanta, GA: American Cancer Society, and New York, NY: World Lung Foundation; 2012.
17. van Boven JFM, Vemer P. Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments. Nicotine Tob Res. 2016;18:56–63.
18. Cadier B, Durand-Zaleski I, Thomas D, Chevreul K, Gorlova OY. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases. PLoS ONE. 2016;11:e0148750.
19. U.S. Food and Drug Administration: Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban [http://www.fda.gov/Drugs/DrugS...]. Accessed 21 Apr 2015.
20. Houtsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav. 2002;72:559–68.
21. Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12:179–83.
22. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. In: Cochrane Database of Systematic Reviews. Chichester: Wiley; 1996.
23. Tonnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013;22:37–43.
24. Tonnesen P, Carrozzi L, Fagerstrom KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2006;29:390–417.
25. KV Spitzenverband: Leitfaden Prävention. Handlungsfelder und Kriterien des GKV-Spitzenverbandes zur Umsetzung von §§ 20 und 20a SGB V vom 21. Juni 2000 in der Fassung vom 27. August 2010. https://www.gkvspitzenverband...... Accessed 22 Aug 2016.
26. National Institute for Health and Care Excellence: Smoking: workplace interventions, Guidance https://www.nice.org.uk/guidan... Accessed 22. Apr 2016.
27. Bethea J, Murtagh B, Wallace SE. “I don’t mind damaging my own body” A qualitative study of the factors that motivate smokers to quit. BMC Public Health. 2015;15:4.
28. Sundblad B, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res. 2008;10:883–90.
29. Abbot NC, Stead LF, White AR, Barnes J: Hypnotherapy for smoking cessation (Review). Cochrane Database of Systematic Review. 1998;2:CD001008. DOI: 10.1002/14651858.CD001008.
 
CITATIONS (1):
1. Tobacco Treatment Guideline for High Risk Groups: A pilot study in patients with Chronic Obstructive Pulmonary Disease
Antigona Trofor, Sophia Papadakis, Lucia Lotrean, Ioana Buculei- Porosnicu, Vergina Vyzikidou, Vaso Evangelopoulou, Constantine Vardavas, Panagiotis Behrakis
Tobacco Induced Diseases
eISSN:1617-9625